Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining

A. Hadar, E. Milanesi, A. Squassina, P. Niola, C. Chillotti, M. Pasmanik-Chor, O. Yaron, P. Martásek, M. Rehavi, D. Weissglas-Volkov, N. Shomron, I. Gozes, D. Gurwitz,

. 2016 ; 6 (10) : e909. [pub] 20161004

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18017010

Alzheimer's disease (AD) is the most frequent cause of dementia. Misfolded protein pathological hallmarks of AD are brain deposits of amyloid-β (Aβ) plaques and phosphorylated tau neurofibrillary tangles. However, doubts about the role of Aβ in AD pathology have been raised as Aβ is a common component of extracellular brain deposits found, also by in vivo imaging, in non-demented aged individuals. It has been suggested that some individuals are more prone to Aβ neurotoxicity and hence more likely to develop AD when aging brains start accumulating Aβ plaques. Here, we applied genome-wide transcriptomic profiling of lymphoblastoid cells lines (LCLs) from healthy individuals and AD patients for identifying genes that predict sensitivity to Aβ. Real-time PCR validation identified 3.78-fold lower expression of RGS2 (regulator of G-protein signaling 2; P=0.0085) in LCLs from healthy individuals exhibiting high vs low Aβ sensitivity. Furthermore, RGS2 showed 3.3-fold lower expression (P=0.0008) in AD LCLs compared with controls. Notably, RGS2 expression in AD LCLs correlated with the patients' cognitive function. Lower RGS2 expression levels were also discovered in published expression data sets from postmortem AD brain tissues as well as in mild cognitive impairment and AD blood samples compared with controls. In conclusion, Aβ sensitivity phenotyping followed by transcriptomic profiling and published patient data mining identified reduced peripheral and brain expression levels of RGS2, a key regulator of G-protein-coupled receptor signaling and neuronal plasticity. RGS2 is suggested as a novel AD biomarker (alongside other genes) toward early AD detection and future disease modifying therapeutics.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017010
003      
CZ-PrNML
005      
20180523131333.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/tp.2016.179 $2 doi
035    __
$a (PubMed)27701409
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hadar, A $u Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
245    10
$a RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining / $c A. Hadar, E. Milanesi, A. Squassina, P. Niola, C. Chillotti, M. Pasmanik-Chor, O. Yaron, P. Martásek, M. Rehavi, D. Weissglas-Volkov, N. Shomron, I. Gozes, D. Gurwitz,
520    9_
$a Alzheimer's disease (AD) is the most frequent cause of dementia. Misfolded protein pathological hallmarks of AD are brain deposits of amyloid-β (Aβ) plaques and phosphorylated tau neurofibrillary tangles. However, doubts about the role of Aβ in AD pathology have been raised as Aβ is a common component of extracellular brain deposits found, also by in vivo imaging, in non-demented aged individuals. It has been suggested that some individuals are more prone to Aβ neurotoxicity and hence more likely to develop AD when aging brains start accumulating Aβ plaques. Here, we applied genome-wide transcriptomic profiling of lymphoblastoid cells lines (LCLs) from healthy individuals and AD patients for identifying genes that predict sensitivity to Aβ. Real-time PCR validation identified 3.78-fold lower expression of RGS2 (regulator of G-protein signaling 2; P=0.0085) in LCLs from healthy individuals exhibiting high vs low Aβ sensitivity. Furthermore, RGS2 showed 3.3-fold lower expression (P=0.0008) in AD LCLs compared with controls. Notably, RGS2 expression in AD LCLs correlated with the patients' cognitive function. Lower RGS2 expression levels were also discovered in published expression data sets from postmortem AD brain tissues as well as in mild cognitive impairment and AD blood samples compared with controls. In conclusion, Aβ sensitivity phenotyping followed by transcriptomic profiling and published patient data mining identified reduced peripheral and brain expression levels of RGS2, a key regulator of G-protein-coupled receptor signaling and neuronal plasticity. RGS2 is suggested as a novel AD biomarker (alongside other genes) toward early AD detection and future disease modifying therapeutics.
650    _2
$a senioři $7 D000368
650    _2
$a Alzheimerova nemoc $x diagnóza $x genetika $x patologie $7 D000544
650    _2
$a amyloidní beta-protein $x genetika $7 D016229
650    _2
$a mozek $x patologie $7 D001921
650    _2
$a buněčné linie $7 D002460
650    _2
$a výpočetní biologie $7 D019295
650    12
$a data mining $7 D057225
650    _2
$a časná diagnóza $7 D042241
650    _2
$a exprese genu $x genetika $7 D015870
650    12
$a stanovení celkové genové exprese $7 D020869
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a genetické markery $x genetika $7 D005819
650    12
$a celogenomová asociační studie $7 D055106
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neurofibrilární klubka $x genetika $x patologie $7 D016874
650    _2
$a fenotyp $7 D010641
650    _2
$a amyloidní plaky $x genetika $x patologie $7 D058225
650    _2
$a proteiny RGS $x genetika $7 D020710
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Milanesi, E $u Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Squassina, A $u Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
700    1_
$a Niola, P $u Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
700    1_
$a Chillotti, C $u Unit of Clinical Pharmacology, University Hospital of Cagliari, Cagliari, Italy.
700    1_
$a Pasmanik-Chor, M $u Bioinformatics Unit, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Yaron, O $u The Genomic Analysis Laboratory, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Martásek, P $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Rehavi, M $u Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.
700    1_
$a Weissglas-Volkov, D $u Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Shomron, N $u Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Adams Super Center for Brain Studies, Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Gozes, I $u Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Adams Super Center for Brain Studies, Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Gurwitz, D $u Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Adams Super Center for Brain Studies, Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
773    0_
$w MED00177206 $t Translational psychiatry $x 2158-3188 $g Roč. 6, č. 10 (2016), s. e909
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27701409 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180523131517 $b ABA008
999    __
$a ok $b bmc $g 1300634 $s 1013850
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 6 $c 10 $d e909 $e 20161004 $i 2158-3188 $m Translational psychiatry $n Transl Psychiatr $x MED00177206
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options